New supplement BK329 shows promise for shedding body fat
NCT ID NCT06628791
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a supplement called BK329 can help reduce body fat in adults who are overweight or have obesity. One hundred participants took either BK329 or a placebo for 12 weeks. Researchers measured changes in total body fat, weight, and other health markers to see if BK329 is effective and safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
100 people
The number who actually took part.
- Started
-
Jan 2024
- Finished
-
Dec 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * individuals with a Body Mass Index (BMI) between 23 and 30 kg/m2. * Individuals who have provided written consent on the consent form. Exclusion Criteria: * Subjects with severe cerebrovascular disease (e.g., stroke, cerebral hemorrhage), heart disease (e.g., angina, myocardial infarction, heart failure, arrhythmia requiring treatment), or malignant tumors within the last 6 months. (However, subjects with a history of these diseases who are clinically stable may participate at the investigator's discretion.) * Uncontrolled hypertensive patients (blood pressure ≥160/100mmHg, measured after 10 minutes of rest). * Diabetic patients with poor blood glucose control (fasting glucose ≥160mg/dL). * Subjects undergoing treatment for hypothyroidism or hyperthyroidism. * Subjects with creatinine levels ≥ 2 times the upper limit of the research institution's normal range. * Subjects with aspartate transaminase or alanine transaminase levels ≥ 3 times the upper limit of the research institution's normal range. * Subjects experiencing severe gastrointestinal symptoms such as heartburn or indigestion (lactose intolerance). * Subjects who have taken weight-altering drugs (absorption inhibitors, appetite suppressants, obesity-related supplements, psychiatric drugs, beta-blockers, diuretics, contraceptives, steroids, or female hormones) within the last month. * Subjects who have participated in commercial weight loss programs within the last 3 months. * Subjects who have participated in or plan to participate in another clinical trial within the last month. * Alcohol abusers. * Subjects who quit smoking within the last 3 months. * Pregnant or breastfeeding women or those planning pregnancy during the trial period. * Subjects with allergies to any components of the study foods. * Subjects deemed inappropriate for the study by the investigator for other reasons.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obesity and overweight are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pusan National University Yangsan Hospital
Yangsan, 50612, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New injection IBI3046 tested for weight management
- One-Size-Fits-All diets may be outdated: personalized plans put to the test
- Can timing your carbs tame metabolic risk?
- Home visits may boost heart health for pregnant women in nigeria
- Could a diabetes drug protect obese Teens' hearts?
- Could a biweekly shot rival weekly Weight-Loss drugs?